Abstract
CASE SUMMARY History After a right radical nephrectomy and pathologic confirmation of perihepatic metastases by computed tomography–guided biopsy, a 50-year-old Caucasian man with renal cell carcinoma was entered into a randomized trial of recombinant interleukin 2 (IL-2) therapy. He had no previous documented allergies. Recombinant IL-2 (Cetus Oncology Division, Chiron Corp, Emeryville, Calif) was reconstituted from lyophilized powder in 5% human serum albumin and administered as a 15-minute infusion (72,000 IU/kg) for a maximum of 15 doses per cycle. The patient was premedicated before each IL-2 infusion with oral acetaminophen and indomethacin, as well as intravenous granisetron. During the sixth cycle of IL-2 treatment, multiple cutaneous lesions of various sizes developed on the face, trunk, and proximal extremities. Similar lesions appeared in the same, as well as in new, locations after one dose of a seventh cycle of IL-2 therapy (Table I).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
